FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Recognizes Genetic Public Database

[ Price : $8.95]

FDA says its recognition of the ClinGen genetic data database will help speed development of novel diagnostic technologies to diag...

FDA Evaluating Mass Spectrometry in Drug Quality Control

[ Price : $8.95]

FDA says its researchers are evaluating a way to use mass spectrometry in drug quality control.

Draft Guide on Noncirrhotic Nonalcoholic Steatohepatitis Drugs

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibros...

Guide on ANDA Post-Complete Response Letter Meetings

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Post-Complete Response Letter Meetings Between FDA and ANDA...

ev3 Agrees to Plead Guilty and Pay $18 Million

[ Price : $8.95]

The U.S. Justice Department announces that medical device manufacturer ev3 has agreed to plead guilty to introducing an adulterate...

FDA Collaborative Communities Update

[ Price : $8.95]

FDA says CDRH is making progress on its strategic goal to facilitate development of collaborative communities.

FDA-483 Issued to JCB Laboratories

[ Price : $8.95]

FDA posts a Form FDA-483 citing JCB Laboratories over GMP deficiencies at the drug outsourcing operation.

Info Collection Extension for e-Adverse Event Reports

[ Price : $8.95]

Federal Register notice: FDA seeks comments on an information collection extension entitled FDA Adverse Event Reports; Electronic ...

Draft Guide on Noncirrhotic Nonalcoholic Steatohepatitis

[ Price : $8.95]

FDA releases a draft guidance entitled Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatme...

Guidance on ANDA Post-complete Response Meetings

[ Price : $8.95]

FDA posts a guidance entitled Post-Complete Response Letter Meetings Between FDA and ANDA Applicants Under GDUFA.